Incidence and risk factors for chronic rejection in pediatric liver transplantation
- PMID: 39311848
- DOI: 10.1097/LVT.0000000000000488
Incidence and risk factors for chronic rejection in pediatric liver transplantation
Abstract
Chronic rejection (CR) is a progressive immunological injury that frequently leads to long-term liver allograft dysfunction and loss. Although CR remains an important indication for retransplantation, as transplant immunosuppression has evolved, its prevalence in adults undergoing liver transplantation (LT) has declined. However, the incidence and factors that lead to CR in pediatric LT are poorly defined. Therefore, we sought to systematically measure CR's incidence and assess both the risk factors for developing CR and outcomes in a large cohort of pediatric recipients of LT. In this single-center study, we retrospectively analyzed and compared relevant recipient characteristics, surgical details, immunosuppression, graft, and patient survival in the CR and control groups over a 17-year period. After a median time of 1.9 years after LT, 19/356 recipients of LT (5.3%) developed CR in our cohort. Posttransplant lymphoproliferative disorder ( p = 0.01), infections ( p = 0.02), autoimmune liver diseases (HR = 7.3, p = <0.01), Black race (HR = 11.5, p = 0.01), and 2 or more episodes of T cell mediated rejection (HR = 5.1, p = <0.01) were associated with CR development. The retransplantation rate among CR cases was 15.8% at a median follow-up time of 4.1 years. Overall, patient survival was lower in the CR group (78.9%) versus controls (91.1%). While CR incidence in our pediatric cohort was lower than previously reported rates of >12%, the CR group had a higher graft failure rate that required retransplantation and lower overall patient survival. Thus, identifying risk factors may warrant specialized immunosuppression protocols and closer posttransplantation monitoring to reduce the risk of morbidity and mortality from CR.
Keywords: T-cell–mediated-rejection (TCMR); autoimmune liver disease; ductopenia; posttransplant lymphoproliferative disease (PTLD).
Copyright © 2024 American Association for the Study of Liver Diseases.
References
-
- Tannuri ACA, Lima F, de Mello ES, Tanigawa RY, Tannuri U. Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation. Clinics (Sao Paulo). 2016;71:216–220.
-
- Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, et al. 2016 comprehensive update of the Banff Working Group on liver allograft pathology: Introduction of antibody-mediated rejection. Am J Transplant. 2016;16:2816–2835.
-
- Wiesner RH, Batts KP, Krom RAF. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Liver Transpl Surg. 1999;5:388–400.
-
- Murphy MS, Harrison R, Davies P, Buckels JA, Mayer AD, Hubscher S, et al. Risk factors for liver rejection: Evidence to suggest enhanced allograft tolerance in infancy. Arch Dis Child. 1996;75:502–506.
-
- Achilleos OA, Mirza DF, Talbot D, McKiernan P, Beath SV, Gunson BK, et al. Outcome of liver retransplantation in children. Liver Transpl Surg. 1999;5:401–406.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources